D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap
Res Pract Thromb Haemost. 2024 Feb 1;8(1):102335. doi: 10.1016/j.rpth.2024.102335. eCollection 2024 Jan.ABSTRACTA State of the Art lecture titled "D-dimer Diagnostics: Can I use any D-dimer assay? Bridging the Knowledge-to-Action gap" was presented at the International Society on Thrombosis and Haemostasis Congress in 2023, included in the session on the clinical impact of variability in commonly used coagulation assays. Here, we review the role of D-dimer, primarily in the outpatient diagnosis of patients with venous thromboembolism (VTE) when combined with clinical decision rules. We focus on the recent large management ...
Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Rita Selby Piet Meijer Emmanuel J Favaloro Source Type: research

Immunothrombosis versus thrombo-inflammation: platelets in cerebrovascular complications
Res Pract Thromb Haemost. 2024 Feb 9;8(1):102344. doi: 10.1016/j.rpth.2024.102344. eCollection 2024 Jan.ABSTRACTA State-of-the Art lecture titled "Thrombo-Neuroinflammatory Disease" was presented at the International Society on Thrombosis and Haemostasis Congress in 2023. First, we would like to advocate for discrimination between immunothrombosis and thrombo-inflammation, as immunothrombosis describes an overshooting inflammatory reaction that results in detrimental thrombotic activity. In contrast, thrombo-inflammation describes the interplay of platelets and coagulation with the immunovascular system, resulting in the r...
Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Lexiao Li David Stegner Source Type: research

A novel factor IXa-specific enzyme-linked immunosorbent assay detects factor IXa in human plasma
CONCLUSION: A monoclonal antibody was developed that specifically detects human FIXa protease. A FIXa-specific ELISA using the new antibody is capable of reproducibly measuring total FIXa in human plasma (both free FIXa and FIXa-antithrombin). This assay should facilitate the evaluation of total FIXa levels in a variety of clinical circumstances.PMID:38433974 | PMC:PMC10907220 | DOI:10.1016/j.rpth.2024.102338 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Tina M Misenheimer Michael R Lasarev Kraig T Kumfer John P Sheehan Bradford S Schwartz Source Type: research

Acquired hemophilia A: a single-center study of 165 patients
CONCLUSION: Immunosuppressive therapies yield remarkably high response rates, with a CR rate exceeding 80%; notably, the regimen containing rituximab exhibits a CR rate of approximately 90%. FVIII inhibitor titer of ≥5 BU/mL and BS of ≥6 were poor predictors of CR in patients with AHA.PMID:38433975 | PMC:PMC10907205 | DOI:10.1016/j.rpth.2024.102318 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Dandan Yu Feng Xue Xiaofan Liu Yunfei Chen Rongfeng Fu Ting Sun Xinyue Dai Mankai Ju Huan Dong Renchi Yang Wei Liu Lei Zhang Source Type: research

D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap
Res Pract Thromb Haemost. 2024 Feb 1;8(1):102335. doi: 10.1016/j.rpth.2024.102335. eCollection 2024 Jan.ABSTRACTA State of the Art lecture titled "D-dimer Diagnostics: Can I use any D-dimer assay? Bridging the Knowledge-to-Action gap" was presented at the International Society on Thrombosis and Haemostasis Congress in 2023, included in the session on the clinical impact of variability in commonly used coagulation assays. Here, we review the role of D-dimer, primarily in the outpatient diagnosis of patients with venous thromboembolism (VTE) when combined with clinical decision rules. We focus on the recent large management ...
Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Rita Selby Piet Meijer Emmanuel J Favaloro Source Type: research

Immunothrombosis versus thrombo-inflammation: platelets in cerebrovascular complications
Res Pract Thromb Haemost. 2024 Feb 9;8(1):102344. doi: 10.1016/j.rpth.2024.102344. eCollection 2024 Jan.ABSTRACTA State-of-the Art lecture titled "Thrombo-Neuroinflammatory Disease" was presented at the International Society on Thrombosis and Haemostasis Congress in 2023. First, we would like to advocate for discrimination between immunothrombosis and thrombo-inflammation, as immunothrombosis describes an overshooting inflammatory reaction that results in detrimental thrombotic activity. In contrast, thrombo-inflammation describes the interplay of platelets and coagulation with the immunovascular system, resulting in the r...
Source: Thrombosis and Haemostasis - March 4, 2024 Category: Hematology Authors: Lexiao Li David Stegner Source Type: research

Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma
CONCLUSION: Clotting and fibrinolysis assays reveal hemostatic effects of replacement and bypassing therapies at clinically relevant concentrations. These assays may help characterize hemostatic agents and optimize dosing.PMID:38426025 | PMC:PMC10901841 | DOI:10.1016/j.rpth.2024.102337 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Lori A Holle Jacob C Pantazis Peter L Turecek Alisa S Wolberg Source Type: research

Accumulating evidence for direct oral anticoagulants in liver disease
Res Pract Thromb Haemost. 2024 Feb 14;8(1):102346. doi: 10.1016/j.rpth.2024.102346. eCollection 2024 Jan.NO ABSTRACTPMID:38426026 | PMC:PMC10904269 | DOI:10.1016/j.rpth.2024.102346 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Karina Meijer Source Type: research

Hematologic characteristics and coagulopathy in pregnancy with COVID-19 succeeding the first wave: a multicenter retrospective cross-sectional study
CONCLUSION: Our findings add valuable insights into the nature of hematologic test characteristics, bleeding, and thrombotic complications for those affected with COVID-19 in pregnancy, reassuring readers of the low incidence of bleeding and thrombotic complications but inviting further debate as to the degree of thromboprophylaxis that may benefit the subgroup with severe disease.PMID:38426027 | PMC:PMC10901829 | DOI:10.1016/j.rpth.2024.102339 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Maha Othman Georgiana Nemeti Marissa Solow Gheorghe Cruciat Daniel Muresan Mariam Suzana Chaikh Sulaiman Shivani Thaker Rezan Abdul-Kadir A Kinga Malinowski Source Type: research

Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?
J Thromb Haemost. 2024 Feb 28:S1538-7836(24)00115-6. doi: 10.1016/j.jtha.2024.02.013. Online ahead of print.ABSTRACTCoagulopathy alongside micro- and macrovascular thrombotic events were frequent characteristics of patients presenting with acute COVID-19 during the initial stages of the pandemic. However, over the past 4 years, the incidence and manifestations of COVID-19-associated coagulopathy have changed due to immunity from natural infection and vaccination, and the appearance of new SARS-CoV-2 variants. Diagnostic criteria and management strategies based on early experience and studies for COVID-19-associated coagulo...
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Toshiaki Iba Jerrold H Levy Cheryl L Maier Jean M Connors Marcel Levi Source Type: research

Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma
CONCLUSION: Clotting and fibrinolysis assays reveal hemostatic effects of replacement and bypassing therapies at clinically relevant concentrations. These assays may help characterize hemostatic agents and optimize dosing.PMID:38426025 | PMC:PMC10901841 | DOI:10.1016/j.rpth.2024.102337 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Lori A Holle Jacob C Pantazis Peter L Turecek Alisa S Wolberg Source Type: research

Accumulating evidence for direct oral anticoagulants in liver disease
Res Pract Thromb Haemost. 2024 Feb 14;8(1):102346. doi: 10.1016/j.rpth.2024.102346. eCollection 2024 Jan.NO ABSTRACTPMID:38426026 | PMC:PMC10904269 | DOI:10.1016/j.rpth.2024.102346 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Karina Meijer Source Type: research

Hematologic characteristics and coagulopathy in pregnancy with COVID-19 succeeding the first wave: a multicenter retrospective cross-sectional study
CONCLUSION: Our findings add valuable insights into the nature of hematologic test characteristics, bleeding, and thrombotic complications for those affected with COVID-19 in pregnancy, reassuring readers of the low incidence of bleeding and thrombotic complications but inviting further debate as to the degree of thromboprophylaxis that may benefit the subgroup with severe disease.PMID:38426027 | PMC:PMC10901829 | DOI:10.1016/j.rpth.2024.102339 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Maha Othman Georgiana Nemeti Marissa Solow Gheorghe Cruciat Daniel Muresan Mariam Suzana Chaikh Sulaiman Shivani Thaker Rezan Abdul-Kadir A Kinga Malinowski Source Type: research

Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?
J Thromb Haemost. 2024 Feb 28:S1538-7836(24)00115-6. doi: 10.1016/j.jtha.2024.02.013. Online ahead of print.ABSTRACTCoagulopathy alongside micro- and macrovascular thrombotic events were frequent characteristics of patients presenting with acute COVID-19 during the initial stages of the pandemic. However, over the past 4 years, the incidence and manifestations of COVID-19-associated coagulopathy have changed due to immunity from natural infection and vaccination, and the appearance of new SARS-CoV-2 variants. Diagnostic criteria and management strategies based on early experience and studies for COVID-19-associated coagulo...
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Toshiaki Iba Jerrold H Levy Cheryl L Maier Jean M Connors Marcel Levi Source Type: research

Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma
CONCLUSION: Clotting and fibrinolysis assays reveal hemostatic effects of replacement and bypassing therapies at clinically relevant concentrations. These assays may help characterize hemostatic agents and optimize dosing.PMID:38426025 | PMC:PMC10901841 | DOI:10.1016/j.rpth.2024.102337 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - March 1, 2024 Category: Hematology Authors: Lori A Holle Jacob C Pantazis Peter L Turecek Alisa S Wolberg Source Type: research